A new targeted drug for psoriatic arthritis, Resoft (upatinib sustained-release tablets), has been approved in China

2022-05-29 0 By

On April 6, 2022, the National Medical Products Administration approved Reifu (upatinib sustained-release tablets) for use in adult patients with active psoriatic arthritis (PsA) who have poor efficacy or intolerance to one or more DMARDs.The recommended dose is 15 mg once daily.Relifor (upatinib sustained-release tablets) is an oral selective Janus kinase (JAK) inhibitor discovered and developed by AbbVie.Ruifu (upatinib sustained-release tablet) will be the first and currently the only targeted therapy for PsA approved in China, which also opens a new era of targeted therapy for PsA in China.PsA is a heterogeneous, systemic and inflammatory disease that can affect multiple body parts including joints and skin, such as peripheral arthritis, attachment inflammation, skin lesions, digitalization (toe) inflammation, axial involvement, digitalization (toe) a, etc.Inflammation caused by the immune system can cause pain, swelling and stiffness in the joints, and even irreversible joint damage, resulting in joint deformation and disability, which can seriously affect the quality of life of patients.In China, the prevalence of PsA ranges from 0.01 to 0.1%.According to The Consensus on diagnosis and Treatment of arthropathic psoriasis in China, the treatment options of PsA in China include non-steroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, biological agents and glucocorticoids, but no targeted drugs have been approved to treat the disease before.Clinical lack of innovative therapies that can comprehensively alleviate disease activity, patients’ treatment needs are far from being met.The approval of Ripford (upatinib sustained-release tablets) has greatly filled the gap in targeted therapies for this disease, giving patients a more powerful weapon against the disease.The approval of Remifu (upatinib sustained-release tablet) is based on data from the Phase 3 selECT-PSA 1 trial, which compared remifu head-to-head with the biologic adamuzumab in patients with PsA.In this study, patients with active PsA treated with 15mg upatinib showed efficacy on multiple disease activity indicators, with effective improvement in joint, body function, fatigue, and skin lesions, and the safety characteristics were consistent with those observed in patients with rheumatoid arthritis.”Many PsA patients have limited treatment options in China,” said Liu Yi, a Chinese principal investigator of the SELect-PSA 1 global study and a professor of rheumatology and Immunology at West China Hospital of Sichuan University.They are eager to find solutions that can help reduce joint pain, swelling and tenderness.With approval from the State Medical Products Administration, upatinib sustained Release tablet, the first targeted therapy for PsA in China, has the opportunity to help more patients suffering from signs and symptoms of psoriatic arthritis achieve meaningful remission and help them set and achieve treatment goals.””Psoriatic arthritis adversely affects many aspects of these patients’ lives.We are proud that Relford will be offered as an entirely new treatment option for PsA patients.Selective Janus kinase (JAK) inhibitors, blessed for, zyban (mpa) in China approved a third indication, is our commitment to patient care standards to improve non-organ-specific rheumatological disorders, and then develop an important milestone in a series of solutions, and reaffirms abbvie long-term leader in the field of immune status.”Beijing Youth Daily reporter Jiang Ruojing editor/Tan Weiping